Product Pipeline
Pharmaxis is a leader in mechanism-based inhibitors of amine oxidases. It has a proven ability to deliver Phase 2 trial ready compounds and an exciting pipeline of drug candidates for valuable targets. Its management team has the long standing expertise in the preclinical, early and late phase clinical trials required to secure successful drug development, as well as the strong industry relationships to deliver global transactions with major pharmaceutical partners.
Pharmaxis' research efforts are focused on discovering new drugs to treat inflammatory and fibrotic diseases such as myelofibrosis, stromal (fibrotic) cancers such as pancreatic and liver cancer, NASH, pulmonary fibrosis, chronic kidney disease, liver fibrosis, fibrotic scarring from burns and other trauma.
Amine oxidase platform
Product Candidate |
Indications |
Pan-LOX; PXS-5505 |
Myelofibrosis |
Pan-LOX; PXS-5505 |
Liver and pancreatic cancer |
LOXL-2; PXS-5382 |
Anti fibrotic |
Pan-LOX; PXS-6302 |
Anti scarring; |
SSAO; PXS-4728A |
isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) Parkinson's disease |
SSAO/MAOB; PXS-4699 |
Anti inflammatory |
SSAO/MPO; PXS-5370 |
Anti inflammatory Multiple indications |